Maccura Biotechnology Co Ltd Total Assets
Maccura Biotechnology Co Ltd total assets. Based on the latest financial reports, Maccura Biotechnology Co Ltd (300463) holds total assets worth CN¥7.82 Billion CNY (≈ $1.14 Billion USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Maccura Biotechnology Co Ltd (300463) market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Maccura Biotechnology Co Ltd (2011–2025)
Total assets of Maccura Biotechnology Co Ltd from 2011 to 2025. This chart illustrates how Maccura Biotechnology Co Ltd's total assets have evolved over time, based on quarterly financial data. See 300463 share price today for real-time trading data and today's change.
Maccura Biotechnology Co Ltd - Asset Composition Analysis
Maccura Biotechnology Co Ltd Total Assets Breakdown (December 2025)
Maccura Biotechnology Co Ltd total assets breakdown as of December 2025. Maccura Biotechnology Co Ltd's total assets of CN¥7.82 Billion consist of 40.4% current assets and 59.6% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 8.4% |
| Accounts Receivable | CN¥1.14 Billion | 14.2% |
| Inventory | CN¥849.13 Million | 10.6% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥519.01 Million | 6.5% |
| Goodwill | CN¥51.04 Million | 0.6% |
Asset Composition Trend (2011–2025)
This chart illustrates how Maccura Biotechnology Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is Maccura Biotechnology Co Ltd's working capital to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Maccura Biotechnology Co Ltd's current assets represent 40.4% of total assets in 2025, a decrease from 71.0% in 2011.
- Cash Position: Cash and equivalents constituted 8.4% of total assets in 2025, down from 20.9% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, an increase from 0.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 14.2% of total assets.
Maccura Biotechnology Co Ltd Competitors by Total Assets
Key competitors of Maccura Biotechnology Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY
|
USA | $12.00 Billion |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882
|
China | CN¥9.20 Billion |
|
Vijaya Diagnostic Centre Limited
NSE:VIJAYA
|
India | Rs15.07 Billion |
|
ALPHAHELIX MOL.DIAGN. SK1
F:4MB
|
Germany | €18.96 Million |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$16.78 Billion |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
|
Australian Clinical Labs Ltd
AU:ACL
|
Australia | AU$562.50 Million |
|
Healius Ltd
AU:HLS
|
Australia | AU$1.77 Billion |
Maccura Biotechnology Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.99 | 3.50 | 2.59 |
| Quick Ratio | 2.91 | 2.48 | 1.87 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥2.34 Billion | CN¥2.54 Billion | CN¥2.48 Billion |
Maccura Biotechnology Co Ltd - Advanced Valuation Insights
This section examines the relationship between Maccura Biotechnology Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.90 |
| Latest Market Cap to Assets Ratio | 0.10 |
| Asset Growth Rate (YoY) | 0.2% |
| Total Assets | CN¥7.99 Billion |
| Market Capitalization | $798.11 Million USD |
Valuation Analysis
Below Book Valuation: The market values Maccura Biotechnology Co Ltd's assets below their book value (0.10x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Maccura Biotechnology Co Ltd's assets grew by 0.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Maccura Biotechnology Co Ltd (2011–2025)
The table below shows the annual total assets of Maccura Biotechnology Co Ltd from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥7.99 Billion ≈ $1.17 Billion |
+0.23% |
| 2024-12-31 | CN¥7.98 Billion ≈ $1.17 Billion |
-1.76% |
| 2023-12-31 | CN¥8.12 Billion ≈ $1.19 Billion |
-0.52% |
| 2022-12-31 | CN¥8.16 Billion ≈ $1.19 Billion |
+24.29% |
| 2021-12-31 | CN¥6.57 Billion ≈ $960.94 Million |
+3.17% |
| 2020-12-31 | CN¥6.36 Billion ≈ $931.40 Million |
+15.79% |
| 2019-12-31 | CN¥5.50 Billion ≈ $804.36 Million |
+20.64% |
| 2018-12-31 | CN¥4.56 Billion ≈ $666.76 Million |
+27.16% |
| 2017-12-31 | CN¥3.58 Billion ≈ $524.33 Million |
+32.79% |
| 2016-12-31 | CN¥2.70 Billion ≈ $394.85 Million |
+13.75% |
| 2015-12-31 | CN¥2.37 Billion ≈ $347.12 Million |
+95.03% |
| 2014-12-31 | CN¥1.22 Billion ≈ $177.99 Million |
+45.32% |
| 2013-12-31 | CN¥837.02 Million ≈ $122.48 Million |
+32.96% |
| 2012-12-31 | CN¥629.52 Million ≈ $92.12 Million |
+24.62% |
| 2011-12-31 | CN¥505.16 Million ≈ $73.92 Million |
-- |
About Maccura Biotechnology Co Ltd
Maccura Biotechnology Co.Ltd engages in the research, development, manufacture, and sale of in vitro diagnostic products; and provides related services for medical laboratories in China and internationally. The company offers laboratory automation solutions, such as hematology analysis workstations; immunoassay products, such as chemiluminescence analyzers and reagents; molecular products, such a… Read more